Details of the Drug

General Information of Drug (ID: DM1IFGT)

Drug Name

Chlorproguanil

Synonyms

Chlorproguanilum; Clorpreguanile; Clorproguanil; Lapudrine; Clorpreguanile [DCIT]; Unspecified HCl of chlorproguanil; Chlorproguanil [INN:BAN]; Chlorproguanilum [INN-Latin]; Clorproguanil [INN-Spanish]; N-(3,4-dichlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; 1-(3,4-Dichlorophenyl)-5-isopropylbiguanide

Indication

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

288.17

Topological Polar Surface Area (xlogp)

3

Rotatable Bond Count (rotbonds)

4

Hydrogen Bond Donor Count (hbonddonor)

3

Hydrogen Bond Acceptor Count (hbondacc)

1

Chemical Identifiers

Formula: C11H15Cl2N5
IUPAC Name: (1E)-1-[amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine
Canonical SMILES: CC(C)N=C(N)/N=C(\\N)/NC1=CC(=C(C=C1)Cl)Cl
InChI: InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)
InChIKey: ISZNZKHCRKXXAU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 9571037
ChEBI ID: CHEBI:135192
CAS Number: 537-21-3
DrugBank ID: DB12314
TTD ID: D0Y2DI

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Polypeptide deformylase (PDF)	TT9SL3Q	DEFM_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Malaria

ICD Disease Classification

1F40-1F45

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Polypeptide deformylase (PDF)	DTT	PDF	8.87E-16	-0.54	-0.86

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
2	Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
3	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4	Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
5	Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
6	Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
7	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
8	Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
9	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.